Small molecule drug developer Sareum Holdings said chief executive Tim Mitchell had presented data demonstrating how a treatment candidate significantly reduced tumour growth. The data were presented in a poster at the American Association for Cancer Research, National Cancer Institute and European Organisation for Research and Treatment of Cancer conference in Boston. The treatment was SDC-1802, a novel selective TYK2/JAK1 inhibitor discovered by Sareum. 'We were pleased to present these data highlighting the anti-tumour effects of our oral TYK2/JAK1 inhibitor SDC-1802 and its immunotherapeutic mechanism yesterday at AACR-NCI-EORTC,' Mitchell said. 'The conference is an important international cancer congress showcasing innovative research from academic and pharmaceutical organisations from around the world.' 'There was a good level of interest directed at novel immunotherapy mechanisms such as TYK2/JAK1 inhibition and we look forward to further discussions with interested parties.' At 8:21am: (LON:SAR) Sareum Holdings PLC share price was +0.02p at 0.35p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.